Trials / Unknown
UnknownNCT01804218
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Invion, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the hypothesis that 18-22 week treatment with the inverse agonist nadolol will improve airway hyperresponsiveness in patients with mild asthma, compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nadolol | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2016-05-01
- First posted
- 2013-03-05
- Last updated
- 2016-08-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01804218. Inclusion in this directory is not an endorsement.